NZ531039A - Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions - Google Patents
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regionsInfo
- Publication number
- NZ531039A NZ531039A NZ531039A NZ53103900A NZ531039A NZ 531039 A NZ531039 A NZ 531039A NZ 531039 A NZ531039 A NZ 531039A NZ 53103900 A NZ53103900 A NZ 53103900A NZ 531039 A NZ531039 A NZ 531039A
- Authority
- NZ
- New Zealand
- Prior art keywords
- human
- constant region
- mouse
- chimeric non
- genes
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims description 31
- 230000009261 transgenic effect Effects 0.000 title description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 198
- 239000012634 fragment Substances 0.000 claims abstract description 125
- 108020004414 DNA Proteins 0.000 claims abstract description 110
- 108700024394 Exon Proteins 0.000 claims abstract description 83
- 108700019146 Transgenes Proteins 0.000 claims abstract description 78
- 210000004602 germ cell Anatomy 0.000 claims abstract description 43
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims abstract description 35
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims abstract description 34
- 230000000392 somatic effect Effects 0.000 claims abstract description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 7
- 210000003917 human chromosome Anatomy 0.000 claims abstract description 7
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 81
- 239000003623 enhancer Substances 0.000 claims description 68
- 238000011830 transgenic mouse model Methods 0.000 claims description 65
- 108060003951 Immunoglobulin Proteins 0.000 claims description 46
- 102000018358 immunoglobulin Human genes 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 46
- 239000012528 membrane Substances 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 230000006798 recombination Effects 0.000 claims description 16
- 238000005215 recombination Methods 0.000 claims description 16
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 10
- 230000037439 somatic mutation Effects 0.000 claims description 10
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 7
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 5
- 241001559589 Cullen Species 0.000 claims 1
- 108010064245 urinary gonadotropin fragment Proteins 0.000 claims 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 abstract description 157
- 241000699666 Mus <mouse, genus> Species 0.000 description 186
- 210000004027 cell Anatomy 0.000 description 171
- 241000699670 Mus sp. Species 0.000 description 138
- 239000013598 vector Substances 0.000 description 105
- 238000012452 Xenomouse strains Methods 0.000 description 81
- 239000000427 antigen Substances 0.000 description 73
- 108091007433 antigens Proteins 0.000 description 73
- 102000036639 antigens Human genes 0.000 description 73
- 239000013612 plasmid Substances 0.000 description 48
- 230000008685 targeting Effects 0.000 description 47
- 241000699660 Mus musculus Species 0.000 description 43
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 36
- 238000009395 breeding Methods 0.000 description 35
- 230000001488 breeding effect Effects 0.000 description 35
- 108091008146 restriction endonucleases Proteins 0.000 description 35
- 230000003053 immunization Effects 0.000 description 33
- 238000002649 immunization Methods 0.000 description 32
- 230000006870 function Effects 0.000 description 30
- 230000004927 fusion Effects 0.000 description 29
- 238000010367 cloning Methods 0.000 description 28
- 241001529936 Murinae Species 0.000 description 26
- 238000011161 development Methods 0.000 description 24
- 230000018109 developmental process Effects 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 22
- 230000008707 rearrangement Effects 0.000 description 22
- 101150050575 URA3 gene Proteins 0.000 description 20
- 239000012636 effector Substances 0.000 description 20
- 210000004408 hybridoma Anatomy 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000003550 marker Substances 0.000 description 18
- 238000010276 construction Methods 0.000 description 17
- 239000013615 primer Substances 0.000 description 17
- 238000012217 deletion Methods 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 230000029087 digestion Effects 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 15
- 238000002105 Southern blotting Methods 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 238000013518 transcription Methods 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 14
- 210000002459 blastocyst Anatomy 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 210000005253 yeast cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 241000609499 Palicourea Species 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108091008875 B cell receptors Proteins 0.000 description 11
- 241000282412 Homo Species 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 10
- 244000309466 calf Species 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 230000016784 immunoglobulin production Effects 0.000 description 10
- 229940072221 immunoglobulins Drugs 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 10
- 210000003519 mature b lymphocyte Anatomy 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 9
- 102100039846 Histone H2B type F-M Human genes 0.000 description 9
- 101001035373 Homo sapiens Histone H2B type F-M Proteins 0.000 description 9
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 9
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 9
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 9
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 9
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 230000011712 cell development Effects 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 102100032412 Basigin Human genes 0.000 description 6
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 6
- 102000008072 Lymphokines Human genes 0.000 description 6
- 108010074338 Lymphokines Proteins 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 5
- 101100179469 Mus musculus Ighg2b gene Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 101150117115 V gene Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000011714 129 mouse Methods 0.000 description 4
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 4
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 4
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 4
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 4
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 102000052611 human IL6 Human genes 0.000 description 4
- 210000003297 immature b lymphocyte Anatomy 0.000 description 4
- 230000034435 immune system development Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000009420 retrofitting Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 101150076615 ck gene Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000001608 teratocarcinoma Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 101150055869 25 gene Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010001160 IgY Proteins 0.000 description 2
- 108700029227 Immunoglobulin Light Chain Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101000767534 Arabidopsis thaliana Chorismate mutase 2 Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 108091067344 C/EBP family Proteins 0.000 description 1
- 102000039548 C/EBP family Human genes 0.000 description 1
- 101150069146 C5 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000252100 Conger Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 101150082479 GAL gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101100496569 Homo sapiens C6 gene Proteins 0.000 description 1
- 101100166833 Homo sapiens CP gene Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 101710132152 Immunoglobulin J chain Proteins 0.000 description 1
- 108700015690 Immunoglobulin Switch Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108050002021 Integrator complex subunit 2 Proteins 0.000 description 1
- 102100033265 Integrator complex subunit 2 Human genes 0.000 description 1
- 102100039133 Integrator complex subunit 6 Human genes 0.000 description 1
- 101710092889 Integrator complex subunit 6 Proteins 0.000 description 1
- 102100030148 Integrator complex subunit 8 Human genes 0.000 description 1
- 101710092891 Integrator complex subunit 8 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 229910009891 LiAc Inorganic materials 0.000 description 1
- 101710122625 Low affinity immunoglobulin gamma Fc region receptor II Proteins 0.000 description 1
- 241001417534 Lutjanidae Species 0.000 description 1
- 101000708578 Milk vetch dwarf virus (isolate N) Para-Rep C3 Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 101000892448 Neisseria gonorrhoeae Type II restriction enzyme NgoMIV Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 241001637516 Polygonia c-album Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150104667 Y-2 gene Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 102000056659 human FcRI Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ542195A NZ542195A (en) | 1999-06-10 | 2000-06-08 | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/329,582 US6833268B1 (en) | 1999-06-10 | 1999-06-10 | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ531039A true NZ531039A (en) | 2005-10-28 |
Family
ID=23286079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ531039A NZ531039A (en) | 1999-06-10 | 2000-06-08 | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| NZ516004A NZ516004A (en) | 1999-06-10 | 2000-06-08 | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ516004A NZ516004A (en) | 1999-06-10 | 2000-06-08 | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6833268B1 (enExample) |
| EP (2) | EP2457439A1 (enExample) |
| JP (3) | JP2003501103A (enExample) |
| KR (2) | KR100891634B1 (enExample) |
| AU (3) | AU778780B2 (enExample) |
| CA (2) | CA2376299C (enExample) |
| HK (1) | HK1047392A1 (enExample) |
| NZ (2) | NZ531039A (enExample) |
| SG (2) | SG147276A1 (enExample) |
| WO (1) | WO2000076310A1 (enExample) |
Families Citing this family (293)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI255853B (en) * | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| MXPA03003407A (es) | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| DK1354034T3 (da) * | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| SK14432003A3 (sk) | 2001-04-26 | 2004-07-07 | Biogen, Inc. | Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie |
| DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| DE50115587D1 (de) | 2001-10-01 | 2010-09-16 | Deutsches Krebsforsch | Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus |
| US7435871B2 (en) * | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| EP1470146B8 (en) * | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| JP2005516965A (ja) | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗ｍｕｃ１８抗体を使用する方法 |
| JP2005514409A (ja) | 2001-12-28 | 2005-05-19 | アブジェニックス・インコーポレーテッド | Ｍｕｃ１８抗原に対する抗体の使用 |
| AU2003209259A1 (en) * | 2002-01-14 | 2003-07-30 | The Board Of Trustees Of The University Of Illinois | Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| CN101745112A (zh) * | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| MXPA05005925A (es) * | 2002-12-02 | 2006-02-08 | Abgenix Inc | Anticuerpos dirigidos a la fosfolipasa a2 y sus usos. |
| JP2007525434A (ja) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。 |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP2395017A3 (en) * | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| JP2007521232A (ja) | 2003-08-08 | 2007-08-02 | アブジェニックス・インコーポレーテッド | 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用 |
| FR2861255B1 (fr) * | 2003-10-24 | 2006-02-17 | Centre Nat Rech Scient | Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications. |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
| WO2005092926A2 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through v gene manipulation |
| MX2007005866A (es) | 2004-11-17 | 2007-11-12 | Amgen Inc | Anticuerpos monoclonales totalmente humanos para il-13. |
| ATE504602T1 (de) | 2004-12-20 | 2011-04-15 | Amgen Fremont Inc | Für humane matriptase spezifische bindungsproteine |
| HRP20110859T1 (hr) | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| WO2006113643A2 (en) | 2005-04-20 | 2006-10-26 | Amgen Fremont Inc. | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies |
| WO2006117699A2 (en) * | 2005-04-29 | 2006-11-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
| CA2629453C (en) | 2005-11-10 | 2018-03-06 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| US7939637B2 (en) | 2005-12-13 | 2011-05-10 | Medimmune Limited | Insulin-like growth factor antibodies and uses thereof |
| JP5179373B2 (ja) | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2007111661A2 (en) | 2006-03-20 | 2007-10-04 | Xoma Technology Ltd. | Human antibodies specific for gastrin materials and methods |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| EP2420246A1 (en) | 2006-04-20 | 2012-02-22 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 1 protein |
| CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2067041A2 (en) | 2006-10-03 | 2009-06-10 | Biogen Idec MA, Inc. | Biomarkers and assays for the treatment of cancer |
| WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
| US7537551B2 (en) * | 2007-01-22 | 2009-05-26 | Brunswick Corporation | Bidirectional resistance apparatus for exercise equipment |
| US20090081237A1 (en) | 2007-03-12 | 2009-03-26 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents |
| EP2602323B1 (en) * | 2007-06-01 | 2018-02-28 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2185719B1 (en) | 2007-08-02 | 2013-11-13 | NovImmune SA | Anti-rantes antibodies and methods of use thereof |
| US9693539B2 (en) * | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| EP2615113A3 (en) | 2007-08-23 | 2013-11-13 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| BRPI0817255A2 (pt) | 2007-09-26 | 2017-06-06 | Amgen Inc | proteínas de ligação a antígeno de fator de crescimento tipo fator de crescimento epidermal de ligação à heparina. |
| EP2220121B1 (en) | 2007-11-12 | 2015-08-19 | U3 Pharma GmbH | Axl antibodies |
| JP5536666B2 (ja) | 2007-12-20 | 2014-07-02 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | 痛風の治療のための方法 |
| FR2926438B1 (fr) * | 2008-01-22 | 2013-01-11 | Univ Limoges | Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe g et ses applications |
| MX2011002837A (es) | 2008-09-19 | 2011-07-29 | Medimmune Llc | Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos. |
| LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
| AU2009331528A1 (en) | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
| CA2755133A1 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
| PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| EP2464220A4 (en) | 2009-08-13 | 2014-05-07 | Crystal Bioscience Inc | Transgenic animal for the production of antibodies with minimal complementarity-determining regions |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| EP3187877A1 (en) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| NO2719708T3 (enExample) | 2009-11-13 | 2018-03-24 | ||
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| IN2012DN06720A (enExample) | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| US8865462B2 (en) * | 2010-01-20 | 2014-10-21 | Crystal Bioscience Inc. | Sustained culture of avian gonocytes |
| KR102004106B1 (ko) | 2010-03-31 | 2019-07-25 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| JP2013540694A (ja) | 2010-08-06 | 2013-11-07 | ウー３・フアルマ・ゲー・エム・ベー・ハー | Ｈｅｒ３結合剤の前立腺治療における使用 |
| US20130177555A1 (en) | 2010-08-13 | 2013-07-11 | Medimmune Limited | Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| WO2012075333A2 (en) | 2010-12-02 | 2012-06-07 | Prometheus Laboratories Inc. | Her2delta16 peptides |
| EP2668207A4 (en) | 2011-01-24 | 2015-06-10 | Univ Singapore | MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES |
| JP5908972B2 (ja) | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2012261933B2 (en) | 2011-06-03 | 2017-06-15 | Xoma Technology Ltd. | Antibodies specific for TGF-beta |
| US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| PE20141937A1 (es) | 2011-11-16 | 2014-12-18 | Amgen Inc | Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| AU2012347540A1 (en) | 2011-12-08 | 2014-06-26 | Amgen Inc. | Agonistic human LCAT antigen binding proteins and their use in therapy |
| EP2794657B1 (en) | 2011-12-19 | 2017-10-11 | Xoma (Us) Llc | Methods for treating acne |
| EP3578569A1 (en) | 2012-02-06 | 2019-12-11 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US9441039B2 (en) | 2012-05-07 | 2016-09-13 | Amgen Inc. | Anti-erythropoietin antibodies |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
| CA2876904C (en) | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
| WO2014022853A1 (en) | 2012-08-03 | 2014-02-06 | Sanford Applied Biosciences, L.L.C. | Complex chromosome engineering for production of human antibodies in transgenic animals |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| ES2728936T3 (es) | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
| KR102276974B1 (ko) | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
| EP2961850A4 (en) * | 2013-02-27 | 2016-10-19 | Academia Sinica | IN-SITU-AFFINITY TREATMENT OF ANTIBODIES |
| AU2014249458A1 (en) | 2013-03-11 | 2015-09-24 | Amgen Inc. | Protein formulations |
| US20140271629A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
| US20160122436A1 (en) | 2013-03-15 | 2016-05-05 | Amgen Research (Munich) Gmbh | Single chain binding molecules comprising n-terminal abp |
| WO2014151834A2 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
| EP2970446A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| KR101882366B1 (ko) | 2013-05-30 | 2018-07-30 | 키닉사 파마슈티컬스, 리미티드 | 온코스타틴 m 수용체 항원 결합 단백질 |
| AU2013396206B2 (en) | 2013-06-28 | 2019-11-14 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| AU2014306564B2 (en) | 2013-08-14 | 2019-10-17 | Antlera Therapeutics Inc. | Antibodies against frizzled proteins and methods of use thereof |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015175874A2 (en) | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| CA2956471C (en) | 2014-07-31 | 2024-09-10 | Amgen Res Munich Gmbh | OPTIMIZED CONSTRUCTIONS OF SINGLE-CATENAL, BI-SPECIFIC, AND CROSS-SPECIFIC ANTIBODY |
| AR101400A1 (es) | 2014-07-31 | 2016-12-14 | Amgen Res Munich Gmbh | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido |
| WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
| GB2547587B (en) * | 2014-10-22 | 2020-12-09 | Crescendo Biologics Ltd | Transgenic mice |
| AU2015350190B2 (en) | 2014-11-18 | 2021-08-05 | Janssen Pharmaceutica Nv | CD47 antibodies, methods, and uses |
| WO2016141111A1 (en) | 2015-03-03 | 2016-09-09 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| JP6901400B2 (ja) | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
| AU2016250023B2 (en) | 2015-04-17 | 2022-02-24 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs for CDH3 and CD3 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| WO2017024285A2 (en) | 2015-08-06 | 2017-02-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US10294303B2 (en) | 2015-12-23 | 2019-05-21 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists |
| PT3411402T (pt) | 2016-02-03 | 2022-02-01 | Amgen Inc | Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3 |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| CA3016474A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| CN118530358A (zh) | 2016-08-01 | 2024-08-23 | 佐马美国有限公司 | 甲状旁腺激素受体1（pth1r）抗体和其用途 |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| BR112019005944A2 (pt) | 2016-09-28 | 2019-06-11 | Musc Foudation For Res Development | anticorpos que se ligam à interleucina 2 e usos dos mesmos |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| US20190263906A1 (en) | 2016-11-10 | 2019-08-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases |
| JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
| SG10202109874VA (en) | 2017-01-19 | 2021-10-28 | Open Monoclonal Tech Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | Univ Queensland | moléculas quiméricas e usos das mesmas |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| SG11201909547TA (en) | 2017-05-05 | 2019-11-28 | Amgen Inc | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
| BR112019024410A2 (pt) | 2017-06-20 | 2020-07-14 | Amgen Inc. | método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1 |
| MX2019015544A (es) | 2017-06-21 | 2020-07-28 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
| CN109321570A (zh) * | 2017-07-31 | 2019-02-12 | 中国科学院上海生命科学研究院 | 用于体外抗体类型转换的方法及试剂盒 |
| CA3071376A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| IL321479A (en) | 2017-12-11 | 2025-08-01 | Amgen Inc | Lengthy manufacturing process for bispecific antibody products |
| TW201940518A (zh) | 2017-12-29 | 2019-10-16 | 美商安進公司 | 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體 |
| EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
| AU2019207895A1 (en) | 2018-01-12 | 2020-06-18 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
| JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| US11440967B2 (en) | 2018-05-31 | 2022-09-13 | Glyconex Inc. | Therapeutic antibodies |
| KR20210041557A (ko) | 2018-07-17 | 2021-04-15 | 후맙스 바이오메드 에스에이 | 캄필로박터 종에 대한 항체 |
| US20210301020A1 (en) | 2018-07-24 | 2021-09-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| CN112771075A (zh) | 2018-07-30 | 2021-05-07 | 安进研发（慕尼黑）股份有限公司 | 结合至cd33和cd3的双特异性抗体构建体的延长施用 |
| CN112512581B (zh) | 2018-08-03 | 2024-12-17 | 安进研发（慕尼黑）股份有限公司 | 针对cldn18.2和cd3的抗体构建体 |
| KR20210052494A (ko) | 2018-08-27 | 2021-05-10 | 아피메트 게엠베하 | 항체 구조물이 사전 로드된 동결 보존된 nk 세포 |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| MX2021003976A (es) | 2018-10-11 | 2021-05-27 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecificos. |
| CA3117433A1 (en) | 2018-10-24 | 2020-04-30 | Deutsches Krebsforschungszentrum Stiftung Des Offentilichen Rechts | Vaccination and antibody generation platform |
| AU2020281378B2 (en) * | 2019-05-30 | 2025-09-11 | Sunshine Lake Pharma Co., Ltd. | Anti-TrkA antibodies and uses thereof |
| MX2021014931A (es) | 2019-06-07 | 2022-01-24 | Amgen Inc | Construcciones de union biespecificas con enlazadores selectivamente escindibles. |
| TWI874409B (zh) | 2019-06-13 | 2025-03-01 | 美商安進公司 | 生物製品製造中基於生物量之自動灌注控制 |
| CA3143524A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
| US20220372138A1 (en) | 2019-07-05 | 2022-11-24 | Iomx Therapeutics Ag | Antibodies binding igc2 of igsf11 (vsig3) and uses thereof |
| EP3763737A1 (en) | 2019-07-12 | 2021-01-13 | Eberhard Karls Universität Tübingen | Binding compounds of penicillin binding protein 2 a |
| US20220281966A1 (en) | 2019-07-26 | 2022-09-08 | Amgen Inc. | Anti-il13 antigen binding proteins |
| AU2020345787A1 (en) | 2019-09-10 | 2022-03-24 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity |
| EP4058485A1 (en) | 2019-11-13 | 2022-09-21 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
| EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| US11926672B2 (en) | 2019-12-20 | 2024-03-12 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| WO2021130383A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| EP4100434A1 (en) | 2020-02-03 | 2022-12-14 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| TWI859420B (zh) | 2020-02-26 | 2024-10-21 | 美商維爾生物科技股份有限公司 | 抗sars-cov-2抗體及使用其之方法 |
| WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| CA3175275A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| EP4135846A1 (en) | 2020-04-14 | 2023-02-22 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| JP2023525039A (ja) | 2020-05-08 | 2023-06-14 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体 |
| JP2023527293A (ja) | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| CA3183693A1 (en) | 2020-05-29 | 2021-12-02 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3 |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| US20230203198A1 (en) | 2020-06-04 | 2023-06-29 | Amgen Inc. | Bispecific binding constructs |
| CA3180477A1 (en) | 2020-06-12 | 2021-12-16 | Elizabeth Alexander | Antibody therapies for sars-cov-2 infection |
| TW202216743A (zh) | 2020-06-26 | 2022-05-01 | 美商安進公司 | Ｉｌ－１０突變蛋白及其融合蛋白 |
| EP4175668A1 (en) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| EP4217385A2 (en) | 2020-09-28 | 2023-08-02 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| EP3992205A1 (en) | 2020-11-03 | 2022-05-04 | Rheinische Friedrich-Wilhelms-Universität Bonn | Sars coronavirus-2 spike protein binding compounds |
| JP2023547507A (ja) | 2020-11-03 | 2023-11-10 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体 |
| EP4240767A1 (en) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Polypeptide constructs binding to cd3 |
| CR20230235A (es) | 2020-11-06 | 2023-10-05 | Amgen Res Munich Gmbh | Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3 |
| CR20230229A (es) | 2020-11-06 | 2023-09-05 | Amgen Res Munich Gmbh | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada |
| CA3198064A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
| WO2022106205A1 (en) | 2020-11-18 | 2022-05-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | Corona virus spike protein binding compounds |
| CN114516917B (zh) * | 2020-11-20 | 2022-11-18 | 广东东阳光药业有限公司 | 人源化抗TrkA的抗体及其应用 |
| JP2023551667A (ja) | 2020-11-23 | 2023-12-12 | ヴィア・バイオテクノロジー・インコーポレイテッド | 抗－インフルエンザ抗体及びその組合せ |
| WO2022109309A1 (en) | 2020-11-23 | 2022-05-27 | Vir Biotechnology, Inc. | Broadly neutralizing antibodies against influenza neuraminidase |
| KR20230135569A (ko) | 2020-11-23 | 2023-09-25 | 비르 바이오테크놀로지, 인코포레이티드 | 인플루엔자 a 바이러스에 대한 항체 |
| WO2022115486A1 (en) | 2020-11-25 | 2022-06-02 | Vir Biotechnology, Inc. | Antibodies that bind to multiple betacoronaviruses |
| CA3203468A1 (en) | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| CA3205586A1 (en) | 2020-12-16 | 2022-06-23 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2022159842A1 (en) | 2021-01-25 | 2022-07-28 | Vir Biotechnology, Inc. | Antibody combination therapies for sars-cov-2 infection |
| CA3206395A1 (en) | 2021-01-28 | 2022-08-04 | Hassan JUMAA-WEINACHT | Method and means for modulating b-cell mediated immune responses |
| CN117120084A (zh) | 2021-01-28 | 2023-11-24 | 维肯芬特有限责任公司 | 用于调节b细胞介导的免疫应答的方法和手段 |
| WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
| US20240101648A1 (en) | 2021-02-09 | 2024-03-28 | Humabs Biomed Sa | Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| AR125290A1 (es) | 2021-04-02 | 2023-07-05 | Amgen Inc | Construcciones de unión a mageb2 |
| EP4330281A1 (en) | 2021-04-29 | 2024-03-06 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
| US20240384006A1 (en) | 2021-05-06 | 2024-11-21 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
| AU2022280767A1 (en) | 2021-05-24 | 2024-01-18 | Humabs Biomed Sa | Engineered polypeptides |
| JP2024527514A (ja) | 2021-06-25 | 2024-07-25 | アムジエン・インコーポレーテツド | Ｔｒｅｍ－１抗原結合タンパク質での循環器疾患の治療 |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| WO2023034866A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | Antibody therapies for sars-cov-2 infection in pediatric subjects |
| WO2023034871A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
| WO2023039442A1 (en) | 2021-09-08 | 2023-03-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| AU2022381918A1 (en) | 2021-11-03 | 2024-06-13 | Affimed Gmbh | Bispecific cd16a binders |
| WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
| WO2023201256A1 (en) | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
| IL316597A (en) | 2022-05-12 | 2024-12-01 | Amgen Res Munich Gmbh | Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity |
| WO2023230448A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Combination immunotherapy for influenza |
| JP2025522295A (ja) | 2022-05-23 | 2025-07-15 | ヒューマブス・バイオメッド・ソシエテ・アノニム | インフルエンザノイラミニダーゼに対する広域中和抗体 |
| WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
| EP4543473A1 (en) | 2022-06-22 | 2025-04-30 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| EP4562034A1 (en) | 2022-07-27 | 2025-06-04 | Humabs Biomed SA | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
| WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
| WO2024112818A1 (en) | 2022-11-22 | 2024-05-30 | Humabs Biomed Sa | Engineered anti-sars-cov-2 antibodies and uses thereof |
| WO2024118998A2 (en) | 2022-12-01 | 2024-06-06 | Vir Biotechnology, Inc. | Engineered anti-sars-cov-2 antibodies and methods of using the same |
| IL321673A (en) | 2022-12-23 | 2025-08-01 | Iomx Therapeutics Ag | LILRB1 and LILRB2 antigen-binding cross-specific proteins, their combinations and uses |
| EP4491230A1 (en) | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| WO2024215762A1 (en) | 2023-04-10 | 2024-10-17 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| WO2024228167A1 (en) | 2023-05-03 | 2024-11-07 | Iox Therapeutics Inc. | Inkt cell modulator liposomal compositions and methods of use |
| WO2024258870A2 (en) | 2023-06-12 | 2024-12-19 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| TW202510911A (zh) | 2023-06-14 | 2025-03-16 | 美商安進公司 | Ｔ細胞接合劑掩蔽分子 |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| WO2025015321A1 (en) | 2023-07-13 | 2025-01-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
| WO2025049858A1 (en) | 2023-09-01 | 2025-03-06 | Amgen Inc. | Molecules for treatment of cancer |
| WO2025096842A2 (en) | 2023-11-03 | 2025-05-08 | Amgen Inc. | Fibroblast targeting molecules |
| WO2025096843A1 (en) | 2023-11-03 | 2025-05-08 | Amgen Inc. | Bispecific molecules |
| WO2025160161A1 (en) | 2024-01-23 | 2025-07-31 | Amgen Inc. | Methods for modulating monoclonal antibody charge variants |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
| US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
1999
- 1999-06-10 US US09/329,582 patent/US6833268B1/en not_active Expired - Lifetime
-
2000
- 2000-06-08 CA CA2376299A patent/CA2376299C/en not_active Expired - Lifetime
- 2000-06-08 KR KR1020077012809A patent/KR100891634B1/ko not_active Expired - Lifetime
- 2000-06-08 CA CA2751621A patent/CA2751621A1/en not_active Abandoned
- 2000-06-08 AU AU54743/00A patent/AU778780B2/en not_active Expired
- 2000-06-08 SG SG200401391-8A patent/SG147276A1/en unknown
- 2000-06-08 NZ NZ531039A patent/NZ531039A/en not_active IP Right Cessation
- 2000-06-08 EP EP10011892A patent/EP2457439A1/en not_active Withdrawn
- 2000-06-08 JP JP2001502667A patent/JP2003501103A/ja not_active Withdrawn
- 2000-06-08 SG SG2007029564A patent/SG173217A1/en unknown
- 2000-06-08 NZ NZ516004A patent/NZ516004A/xx not_active IP Right Cessation
- 2000-06-08 HK HK02107181.2A patent/HK1047392A1/zh unknown
- 2000-06-08 WO PCT/US2000/015782 patent/WO2000076310A1/en not_active Ceased
- 2000-06-08 EP EP00939693A patent/EP1191839A1/en not_active Withdrawn
- 2000-06-08 KR KR1020017015876A patent/KR100855998B1/ko not_active Expired - Lifetime
-
2001
- 2001-11-30 US US09/999,321 patent/US7049426B2/en not_active Expired - Lifetime
-
2003
- 2003-01-21 US US10/349,706 patent/US20030208781A1/en not_active Abandoned
-
2005
- 2005-01-24 AU AU2005200279A patent/AU2005200279C1/en not_active Expired
- 2005-09-09 US US11/223,359 patent/US7547817B2/en not_active Expired - Fee Related
-
2008
- 2008-07-02 AU AU2008202912A patent/AU2008202912A1/en not_active Abandoned
-
2010
- 2010-12-07 JP JP2010272134A patent/JP2011087594A/ja active Pending
-
2013
- 2013-09-30 JP JP2013202875A patent/JP2014003984A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005200279B2 (en) | 2008-04-03 |
| JP2011087594A (ja) | 2011-05-06 |
| JP2014003984A (ja) | 2014-01-16 |
| KR100891634B1 (ko) | 2009-04-03 |
| US20030208781A1 (en) | 2003-11-06 |
| AU2005200279A1 (en) | 2005-02-17 |
| KR100855998B1 (ko) | 2008-09-03 |
| WO2000076310A1 (en) | 2000-12-21 |
| SG173217A1 (en) | 2011-08-29 |
| KR20070085842A (ko) | 2007-08-27 |
| AU778780B2 (en) | 2004-12-23 |
| WO2000076310A9 (en) | 2002-07-18 |
| JP2003501103A (ja) | 2003-01-14 |
| NZ516004A (en) | 2004-03-26 |
| CA2751621A1 (en) | 2000-12-21 |
| US6833268B1 (en) | 2004-12-21 |
| EP2457439A1 (en) | 2012-05-30 |
| EP1191839A1 (en) | 2002-04-03 |
| AU5474300A (en) | 2001-01-02 |
| CA2376299A1 (en) | 2000-12-21 |
| SG147276A1 (en) | 2008-11-28 |
| US20060134780A1 (en) | 2006-06-22 |
| HK1047392A1 (zh) | 2003-02-21 |
| AU2005200279C1 (en) | 2008-09-04 |
| CA2376299C (en) | 2011-11-01 |
| US7547817B2 (en) | 2009-06-16 |
| AU2008202912A1 (en) | 2008-07-24 |
| KR20020019071A (ko) | 2002-03-09 |
| US7049426B2 (en) | 2006-05-23 |
| US20030093820A1 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005200279B2 (en) | Transgenic Animals for Producing Specific Isotypes of Human Antibodies Via Non-Cognate Switch Regions | |
| JP6545773B2 (ja) | ハイブリッド軽鎖マウス | |
| CA2124967C (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
| CA2161351C (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
| JP2938569B2 (ja) | 異種免疫グロブリンを作る方法及びトランスジェニックマウス | |
| US5789650A (en) | Transgenic non-human animals for producing heterologous antibodies | |
| WO2004076618A9 (en) | Genetically modified non-human mammals and cells | |
| JPH11206387A (ja) | 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス | |
| AU781922B2 (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
| NZ542195A (en) | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions | |
| HK1171337A (en) | Transgenic non-human animals for producing specific isotypes of human antibodies via non-cognate switch regions | |
| AU743883B2 (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
| AU2003204055B2 (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
| AU720612B2 (en) | Transgenic non-human animals capable of producing heterologous antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 08 JUN 2020 BY COMPUTER PACKAGES INC Effective date: 20130709 |
|
| EXPY | Patent expired |